These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 39144292)

  • 21. A Clinical Analysis of Anti-Programmed Death-Ligand 1 (PD-L1) Immune Checkpoint Inhibitor Treatments Combined with Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer.
    Hsu PC; Wu BC; Wang CC; Chiu LC; Chang CH; Liu PC; Wu CE; Kuo SC; Ju JS; Huang AC; Lin YC; Yang CT; Ko HW
    Vaccines (Basel); 2024 Apr; 12(5):. PubMed ID: 38793725
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-analysis.
    Zhou T; Zhang Z; Luo F; Zhao Y; Hou X; Liu T; Wang K; Zhao H; Huang Y; Zhang L
    JAMA Netw Open; 2020 Oct; 3(10):e2015748. PubMed ID: 33074323
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer.
    Yu H; Chen P; Cai X; Chen C; Zhang X; He L; Zhou Y; Hong S; Zhang B
    Cancer Immunol Immunother; 2022 Mar; 71(3):637-644. PubMed ID: 34297160
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Efficacy and Safety of Anlotinib in Extensive-Stage Small Cell Lung Cancer: A Multicenter Real-World Study.
    Zheng HR; Jiang AM; Gao H; Liu N; Zheng XQ; Fu X; Zhang R; Ruan ZP; Tian T; Liang X; Yao Y
    Cancer Manag Res; 2022; 14():2273-2287. PubMed ID: 35942069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China.
    Zhang X; Zeng L; Li Y; Xu Q; Yang H; Lizaso A; Mao X; Jin R; Zeng Y; Li Q; Wang J; Li Y; Zhang Y; Yang N
    Cancer Immunol Immunother; 2021 Sep; 70(9):2517-2528. PubMed ID: 33566148
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of first-line PD-L1/PD-1 inhibitors in limited-stage small cell lung cancer: a multicenter propensity score matched retrospective study.
    Xie J; Xu K; Cai Z; Chen M; Jiang Y; Ye J; Lin X; Lv T; Zhan P
    Transl Lung Cancer Res; 2024 Mar; 13(3):526-539. PubMed ID: 38601454
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety analysis of anlotinib in combination with immune checkpoint inhibitors for second-line and subsequent extensive-stage small-cell lung cancer.
    Ying X; Shi Z; Shao R; You G; Song Z
    Neoplasma; 2024 Jun; 71(3):297-305. PubMed ID: 38958712
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of novel immune checkpoint inhibitor-based combinations versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer: A network meta-analysis.
    Yang C; Xuan T; Gong Q; Dai X; Wang C; Zhang R; Zhao W; Wang J; Yue W; Li J
    Thorac Cancer; 2024 May; 15(15):1246-1262. PubMed ID: 38623838
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Carrelizumab combined with anlotinib in the treatment of extensive-stage small cell lung cancer: A case report.
    Liu L; Zhang X; Zhou L; Yang T; Qiao Y; Jiang X
    Medicine (Baltimore); 2021 Sep; 100(35):e27138. PubMed ID: 34477165
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer: a nonrandomized clinical trial.
    Ni J; Si X; Wang H; Zhang X; Zhang L
    Front Immunol; 2023; 14():1168879. PubMed ID: 37114054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Non-Small-Cell Lung Cancer After Previous Systemic Treatment Failure-A Retrospective Study.
    Wang P; Fang X; Yin T; Tian H; Yu J; Teng F
    Front Oncol; 2021; 11():628124. PubMed ID: 33791214
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of anlotinib combined with carboplatin and pemetrexed as first-line induction therapy followed by anlotinib plus pemetrexed as maintenance therapy in
    He Z; Yang X; Ma T; Yang Q; Zhang C; Chen Y; Wang P; D'Incecco A; Metro G; Uematsu S; Wang Q
    Transl Lung Cancer Res; 2022 Aug; 11(8):1657-1666. PubMed ID: 36090635
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term survival in extensive-stage small-cell lung cancer treated with different immune checkpoint inhibitors in multiple-line therapies: A case report and literature review.
    Zhang X; Zheng J; Niu Y; Xue C; Yu Y; Tan K; Cui H
    Front Immunol; 2022; 13():1059331. PubMed ID: 36532013
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical efficacy and safety of immune checkpoint inhibitors plus anlotinib as secondline or subsequent therapy in extensive stage small cell lung cancer: a retrospective study.
    Wu Y; Zhang Y; Tian Y; Lv Y; Zhang J
    Clin Transl Oncol; 2024 Aug; ():. PubMed ID: 39115676
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paclitaxel liposome (Lipusu) based chemotherapy combined with immunotherapy for advanced non-small cell lung cancer: a multicenter, retrospective real-world study.
    Li R; Liang H; Li J; Shao Z; Yang D; Bao J; Wang K; Xi W; Gao Z; Guo R; Mu X
    BMC Cancer; 2024 Jan; 24(1):107. PubMed ID: 38238648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer.
    Melosky B; Cheema PK; Brade A; McLeod D; Liu G; Price PW; Jao K; Schellenberg DD; Juergens R; Leighl N; Chu Q
    Oncologist; 2020 Nov; 25(11):981-992. PubMed ID: 32860288
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful Treatment of a Patient With Multiple-Line Relapsed Extensive-Stage Small-Cell Lung Cancer Receiving Penpulimab Combined With Anlotinib: A Case Report.
    Zhang Z; Li Y; Dong Y; Li J; Zhang B; Zhang C; Cui X
    Front Oncol; 2022; 12():846597. PubMed ID: 35321433
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of first-line PD-1/PD-L1 inhibitor combinations for extensive-stage small-cell lung cancer: a Bayesian network meta-analysis.
    Li H; Han H; Li C; Wu R; Wang Z; Wang Y; Zhan P; Lv T; Zhang F; Song Y; Liu H
    Ther Adv Med Oncol; 2023; 15():17588359231189430. PubMed ID: 37885460
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anlotinib plus platinum-etoposide as a first-line treatment for extensive-stage small cell lung cancer: A single-arm trial.
    Deng P; Hu C; Chen C; Cao L; Gu Q; An J; Qin L; Li M; He B; Jiang J; Yang H
    Cancer Med; 2022 Oct; 11(19):3563-3571. PubMed ID: 35526266
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Response to first-line treatment predicts progression-free survival benefit of small-cell lung cancer patients treated with anlotinib.
    Qin B; Xin L; Hou Q; Yang B; Zhang J; Qi X; Wei Y; Hu Y; Xiong Q
    Cancer Med; 2021 Jun; 10(12):3896-3904. PubMed ID: 33960145
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.